2026-06-14T03:50:52Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/180462024-11-28T15:03:25Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16978

00925njm 22002777a 4500 dc Salvador-Martín, Sara author Raposo-Gutiérrez, Irene author Navas-López, Víctor Manuel author Gallego-Fernández, Carmen author Moreno-Álvarez, Ana author Solar-Boga, Alfonso author Muñoz-Codoceo, Rosana author Magallares, Lorena author Martínez-Ojinaga, Eva author Fobelo, María J. author Millán-Jiménez, Antonio author Rodriguez-Martinez, Alejandro author Vayo, Concepción A. author Sánchez, Cesar author Tolin, Mar author Bossacoma, Ferrán author Pujol-Muncunill, Gemma author González de Caldas, Rafael author Loverdos, Inés author Blanca-García, José A. author Segarra, Oscar author Eizaguirre, Francisco J. author García-Romero, Ruth author Merino-Bohórquez, Vicente author Sanjurjo-Sáez, María author López-Fernández, Luis A. author 2020-05-09 Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2-∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies. 10.3390/ijms21093364 1422-0067 International Journal of Molecular Sciences http://hdl.handle.net/10668/3700 32397546 http://hdl.handle.net/20.500.12105/18046 Biomarker Gene expression Infliximab Adalimumab Ulcerative colitis Crohn’s disease Biomarcadores Expresión génica Colitis ulcerosa Enfermedad de Crohn Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease